Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/cancer-immunotherapy-comes-of-age-4Z7f6BBPRc
References (182)
-
J. Gadiot, A. Hooijkaas, A. Kaiser, H. Tinteren, H. Boven, C. Blank (2011)
Overall survival and PD‐L1 expression in metastasized malignant melanomaCancer, 117
-
M. Keir, M. Butte, G. Freeman, A. Sharpe (2008)
PD-1 and its ligands in tolerance and immunity.Annual review of immunology, 26
-
E. Trombetta, I. Mellman (2005)
Cell biology of antigen processing in vitro and in vivo.Annual review of immunology, 23
-
G. Weiner (2010)
Rituximab: mechanism of action.Seminars in hematology, 47 2
-
S. Rosenberg, N. Restifo, J. Yang, R. Morgan, M. Dudley (2008)
Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 8
-
H Gogas (2006)
10.1056/NEJMoa053007N. Engl. J. Med., 354
-
C. June (2007)
Principles of adoptive T cell cancer therapy.The Journal of clinical investigation, 117 5
-
A. Cohen, David Schaer, Cailian Liu, Yanyun Li, Daniel Hirschhorn-Cymmerman, Soochi Kim, A. Diab, G. Rizzuto, F. Duan, M. Perales, T. Merghoub, A. Houghton, J. Wolchok (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor AccumulationPLoS ONE, 5
-
R. Clynes, Terri Towers, L. Presta, J. Ravetch (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNature Medicine, 6
-
I. Alagkiozidis, A. Facciabene, M. Tsiatas, C. Carpenito, F. Benencia, S. Adams, Z. Jonak, C. June, D. Powell, G. Coukos (2011)
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapyJournal of Translational Medicine, 9
-
Julie Bowles, Siao-Yi Wang, B. Link, B. Allan, G. Beuerlein, M. Campbell, D. Marquis, B. Ondek, J. Wooldridge, Brian Smith, J. Breitmeyer, G. Weiner (2005)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.Blood, 108 8
-
M. Krauze, A. Tarhini, H. Gogas, J. Kirkwood (2006)
Prognostic significance of autoimmunity during treatment of melanoma with interferonSeminars in Immunopathology, 33
-
M. Kalos, B. Levine, D. Porter, Sharyn Katz, S. Grupp, A. Bagg, C. June (2011)
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 3
-
D. McDermott, Charles Drake, M. Sznol, J. Sosman, David Smith, J. Powderly, D. Feltquate, G. Kollia, A. Gupta, J. Wigginton (2011)
A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 7_suppl
-
C. Robert, L. Thomas, I. Bondarenko, S. O'Day, J. Weber, C. Garbe, C. Lebbé, J. Baurain, A. Testori, J. Grob, N. Davidson, J. Richards, M. Maio, A. Hauschild, W. Miller, P. Gascón, M. Lotem, K. Harmankaya, R. Ibrahim, S. Francis, Tai-Tsang Chen, R. Humphrey, A. Hoos, J. Wolchok (2011)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.The New England journal of medicine, 364 26
-
L. Kelland (2006)
Discontinued drugs in 2005: oncology drugsExpert Opinion on Investigational Drugs, 15
-
A recent and clinically impressive attempt at adoptive T-cell therapy using genetically altered, patient-derived T cells -
K. Palucka, J. Banchereau, I. Mellman (2010)
Designing vaccines based on biology of human dendritic cell subsets.Immunity, 33 4
-
Andrew Pawluczkowycz, F. Beurskens, P. Beum, M. Lindorfer, J. Winkel, P. Parren, R. Taylor (2009)
Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX1The Journal of Immunology, 183
-
A. Freedman, S. Neelapu, C. Nichols, M. Robertson, B. Djulbegovic, J. Winter, J. Bender, D. Gold, R. Ghalie, M. Stewart, V. Esquibel, P. Hamlin (2009)
Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 18
-
F. Ghiringhelli, L. Apetoh, A. Tesnière, L. Aymeric, Yuting Ma, Carla Ortiz, K. Vermaelen, T. Panaretakis, G. Mignot, E. Ullrich, J. Perfettini, F. Schlemmer, E. Tasdemir, M. Uhl, P. Génin, A. Civas, B. Ryffel, J. Kanellopoulos, J. Tschopp, F. André, R. Lidereau, N. McLaughlin, N. Haynes, M. Smyth, G. Kroemer, L. Zitvogel (2009)
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumorsNature Medicine, 15
-
S. Dall'ozzo, S. Tartas, G. Paintaud, G. Cartron, P. Colombat, P. Bardos, H. Watier, G. Thibault (2004)
Rituximab-Dependent Cytotoxicity by Natural Killer Cells: Influence of FCGR3A Polymorphism on the Concentration-Effect Relationship -
Hiroyuki Nishimura, M. Nose, H. Hiai, N. Minato, T. Honjo (1999)
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.Immunity, 11 2
-
S. Hall (1997)
A Commotion in the Blood: Life, Death, and the Immune System -
M. Disis (2010)
Immune regulation of cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 29
-
A. Thomas, Lynn Santarsiero, Eric Lutz, T. Armstrong, Yi‐Cheng Chen, Lan Huang, D. Laheru, M. Goggins, R. Hruban, E. Jaffee (2004)
Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer PatientsThe Journal of Experimental Medicine, 200
-
A. Younes, N. Bartlett, J. Leonard, D. Kennedy, C. Lynch, E. Sievers, A. Forero-Torres (2010)
Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.The New England journal of medicine, 363 19
-
M. Dougan, S. Dougan, J. Slisz, B. Firestone, Matthew Vanneman, Dobrin Draganov, G. Goyal, Weibo Li, D. Neuberg, R. Blumberg, N. Hacohen, D. Porter, L. Zawel, G. Dranoff (2010)
IAP inhibitors enhance co-stimulation to promote tumor immunityThe Journal of Experimental Medicine, 207
-
F. Hodi, M. Butler, D. Oble, M. Seiden, M. Seiden, F. Haluska, A. Kruse, Suzanne Macrae, Marybeth Nelson, C. Canning, I. Lowy, A. Korman, D. Lautz, Sara Russell, M. Jaklitsch, N. Ramaiya, Teresa Chen, D. Neuberg, J. Allison, M. Mihm, G. Dranoff (2008)
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patientsProceedings of the National Academy of Sciences, 105
-
H. Rammensee, T. Weinschenk, C. Gouttefangeas, Stefan Eq (2002)
Towards patient‐specific tumor antigen selection for vaccinationImmunological Reviews, 188
-
H Gogas (2006)
Prognostic significance of autoimmunity during treatment of melanoma with interferonN. Engl. J. Med., 354
-
C. Hudis (2007)
Trastuzumab--mechanism of action and use in clinical practice.The New England journal of medicine, 357 1
-
A. Muller, P. Scherle (2006)
Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitorsNature Reviews Cancer, 6
-
N. Renkvist, C. Castelli, P. Robbins, G. Parmiani (2001)
A listing of human tumor antigens recognized by T cellsCancer Immunology, Immunotherapy, 50
-
E. Tivol, F. Borriello, A. Schweitzer, William Lynch, J. Bluestone, Arlene Sharpe (1995)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.Immunity, 3 5
-
A. Cipponi, Grégoire Wieers, N. Baren, P. Coulie (2011)
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?Cancer Immunology, Immunotherapy, 60
-
G. Darrasse-Jéze, S. Deroubaix, H. Mouquet, G. Victora, Thomas Eisenreich, Kai-Hui Yao, Revati Masilamani, Michael Dustin, A. Rudensky, Kang Liu, M. Nussenzweig (2009)
Feedback control of regulatory T cell homeostasis by dendritic cells in vivoThe Journal of Experimental Medicine, 206
-
M. Sznol, J. Powderly, David Smith, J. Brahmer, C. Drake, D. McDermott, D. Lawrence, J. Wolchok, S. Topalian, I. Lowy (2010)
Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies.Journal of Clinical Oncology, 28
-
M. Disis, S. Pupa, J. Gralow, R. Dittadi, Sylvie Ménard, M. Cheever (1997)
High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 15 11
-
(2011)
apparently good for melanoma patients -
D. Schwartzentruber, S. Hom, R. Dadmarz, D. White, J. Yannelli, S. Steinberg, S. Rosenberg, S. Topalian (1994)
In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 7
-
Betty Li, M. Vanroey, Changyu Wang, Tseng-Hui Chen, A. Korman, K. Jooss (2009)
Anti–Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor–Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established TumorsClinical Cancer Research, 15
-
(2011)
Anti-PD-1 and -B7–H1/PD-L1 monoclonal antibodies, in Gajewski TF, Hodi FS (eds): Targeted Therapeutics in Melanoma -
Siao-Yi Wang, E. Racila, R. Taylor, G. Weiner (2008)
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.Blood, 111 3
-
A. Hoos, A. Eggermont, S. Janetzki, F. Hodi, Ramy Ibrahim, Aparna Anderson, Rachel Humphrey, Brent Blumenstein, L. Old, J. Wolchok (2010)
Improved Endpoints for Cancer Immunotherapy TrialsJNCI Journal of the National Cancer Institute, 102
-
Ching-Tai Huang, C. Workman, D. Flies, Xiaoyu Pan, A. Marson, Gang Zhou, Edward Hipkiss, S. Ravi, J. Kowalski, H. Levitsky, J. Powell, D. Pardoll, C. Drake, D. Vignali (2004)
Role of LAG-3 in regulatory T cells.Immunity, 21 4
-
R. Vanwijck, J. Bernheim, F. Lejeune (1974)
[Immunology of melanoma].Acta chirurgica Belgica, 73 2
-
R. Humphrey, Laura Brockway-Lunardi, David Bonk, K. Dohoney, J. Doroshow, S. Meech, M. Ratain, S. Topalian, D. Pardoll (2011)
Opportunities and challenges in the development of experimental drug combinations for cancer.Journal of the National Cancer Institute, 103 16
-
J. Wolchok, A. Hoos, S. O'Day, J. Weber, O. Hamid, C. Lebbé, M. Maio, Michael Binder, O. Bohnsack, G. Nichol, R. Humphrey, Stephen Hodi (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response CriteriaClinical Cancer Research, 15
-
P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small, D. Penson, C. Redfern, A. Ferrari, R. Dreicer, R. Sims, Yi Xu, M. Frohlich, P. Schellhammer (2010)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.The New England journal of medicine, 363 5
-
M. Topp, P. Kufer, N. Gökbuget, M. Goebeler, M. Klinger, S. Neumann, H. Horst, T. Raff, A. Viardot, M. Schmid, M. Stelljes, M. Schaich, Evelyn Degenhard, R. Köhne-Volland, M. Brüggemann, O. Ottmann, H. Pfeifer, T. Burmeister, D. Nagorsen, Margit Schmidt, R. Lutterbuese, C. Reinhardt, P. Baeuerle, M. Kneba, H. Einsele, G. Riethmüller, D. Hoelzer, G. Zugmaier, R. Bargou (2011)
Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 18
-
C. Workman, D. Vignali (2005)
Negative Regulation of T Cell Homeostasis by Lymphocyte Activation Gene-3 (CD223)1The Journal of Immunology, 174
-
G. Beatty, E. Chiorean, Matthew Fishman, B. Saboury, U. Teitelbaum, Weijing Sun, R. Huhn, Wenru Song, Dongguang Li, L. Sharp, D. Torigian, P. O'dwyer, R. Vonderheide (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and HumansScience, 331
-
N. Senzer, H. Kaufman, T. Amatruda, M. Nemunaitis, T. Reid, G. Daniels, R. Gonzalez, J. Glaspy, E. Whitman, K. Harrington, H. Goldsweig, T. Marshall, C. Love, R. Coffin, J. Nemunaitis (2009)
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 34
-
Stephanie Harbers, Andrea Crocker, G. Catalano, V. D’Agati, Steffen Jung, D. Desai, R. Clynes (2007)
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance.The Journal of clinical investigation, 117 5
-
D. Munn, A. Mellor (2004)
IDO and tolerance to tumors.Trends in molecular medicine, 10 1
-
Seng-Ryong Woo, Nianyu Li, T. Bruno, K. Forbes, Scott Brown, C. Workman, C. Drake, D. Vignali (2010)
Differential subcellular localization of the regulatory T‐cell protein LAG‐3 and the coreceptor CD4European Journal of Immunology, 40
-
S. Jensen, L. Maston, M. Gough, Carl Ruby, William Redmond, M. Crittenden, Yuhuan Li, Sachin Puri, C. Poehlein, N. Morris, M. Kovacsovics-Bankowski, T. Moudgil, C. Twitty, E. Walker, Hong-Ming Hu, W. Urba, A. Weinberg, B. Curti, B. Fox (2010)
Signaling through OX40 enhances antitumor immunity.Seminars in oncology, 37 5
-
R. Steinman, S. Turley, I. Mellman, K. Inaba (2000)
The Induction of Tolerance by Dendritic Cells That Have Captured Apoptotic CellsThe Journal of Experimental Medicine, 191
-
K. Kono, Hiromichi Kawaida, Akihiro Takahashi, H. Sugai, Kosaku Mimura, Naoto Miyagawa, H. Omata, H. Fujii (2006)
CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancersCancer Immunology, Immunotherapy, 55
-
S. Treon, M. Hansen, A. Branagan, S. Verselis, C. Emmanouilides, E. Kimby, S. Frankel, N. Touroutoglou, B. Turnbull, K. Anderson, D. Maloney, E. Fox (2005)
Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 3
-
P. Kantoff, T. Schuetz, Brent Blumenstein, L. Glodé, D. Bilhartz, M. Wyand, K. Manson, D. Panicali, R. Laus, J. Schlom, William Dahut, P. Arlen, J. Gulley, Wayne Godfrey (2010)
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 7
-
R. Sylvester (2011)
Bacillus Calmette–Guérin treatment of non‐muscle invasive bladder cancerInternational Journal of Urology, 18
-
A. Ribas (2010)
Clinical development of the anti-CTLA-4 antibody tremelimumab.Seminars in oncology, 37 5
-
RM Steinman (2003)
10.1146/annurev.immunol.21.120601.141040Annu. Rev. Immunol., 21
-
D. Schwartzentruber, D. Lawson, J. Richards, R. Conry, Donald Miller, J. Treisman, F. Gailani, L. Riley, K. Conlon, B. Pockaj, K. Kendra, R. White, Rene Gonzalez, T. Kuzel, B. Curti, P. Leming, E. Whitman, J. Balkissoon, D. Reintgen, H. Kaufman, F. Marincola, M. Merino, S. Rosenberg, P. Choyke, D. Vena, P. Hwu (2011)
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.The New England journal of medicine, 364 22
-
R. Chakraverty, S. Mackinnon (2011)
Allogeneic transplantation for lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 14
-
N. Hunder, H. Wallen, Jianhong Cao, Deborah Hendricks, J. Reilly, Rebecca Rodmyre, A. Jungbluth, S. Gnjatic, John Thompson, C. Yee (2008)
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.The New England journal of medicine, 358 25
-
D. Pardoll, S. Topalian (1998)
The role of CD4+ T cell responses in antitumor immunity.Current opinion in immunology, 10 5
-
T. Kawai, S. Akira (2011)
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity.Immunity, 34 5
-
H. Gerber, May Kung-Sutherland, I. Stone, Carol Morris-Tilden, J. Miyamoto, R. Mccormick, S. Alley, N. Okeley, Brad Hayes, F. Hernandez-Ilizaliturri, C. McDonagh, P. Carter, Dennis Benjamin, I. Grewal (2009)
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.Blood, 113 18
-
A. Sharpe, G. Freeman (2002)
The B7–CD28 superfamilyNature Reviews Immunology, 2
-
Xiao-song Zhong, M. Matsushita, J. Plotkin, I. Rivière, M. Sadelain (2010)
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.Molecular therapy : the journal of the American Society of Gene Therapy, 18 2
-
M. Neller, J. Lopez, C. Schmidt (2008)
Antigens for cancer immunotherapy.Seminars in immunology, 20 5
-
J. Spivak (2002)
Polycythemia vera: myths, mechanisms, and management.Blood, 100 13
-
L. Zitvogel, G. Kroemer (2009)
Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects.The Journal of clinical investigation, 119 8
-
J. Brahmer, C. Drake, I. Wollner, J. Powderly, J. Picus, W. Sharfman, E. Stankevich, A. Pons, Theresa Salay, T. McMiller, Marta Gilson, Changyu Wang, M. Selby, J. Taube, R. Anders, Lieping Chen, A. Korman, D. Pardoll, I. Lowy, S. Topalian (2010)
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 19
-
Haidong Dong, S. Strome, D. Salomão, H. Tamura, F. Hirano, D. Flies, P. Roche, Jun Lu, G. Zhu, K. Tamada, V. Lennon, E. Celis, Lieping Chen (2002)
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 8
-
J. Copier, A. Dalgleish (2010)
Whole-cell vaccines: A failure or a success waiting to happen?Current opinion in molecular therapeutics, 12 1
-
W. Zou, Lieping Chen (2008)
Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 8
-
A. Velardi (2008)
Role of KIRs and KIR ligands in hematopoietic transplantation.Current opinion in immunology, 20 5
-
D. Lowy, Ian Frazer (1998)
Cancer vaccinesInpharma Weekly, 1130
-
Anti - PD - 1 and - B 7 – H 1 / PD - L 1 monoclonal antibodies -
K. Sakuishi, L. Apetoh, Jenna Sullivan, B. Blazar, V. Kuchroo, A. Anderson (2010)
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 207
-
Clare Taylor, D. Hershman, Nina Shah, N. Suciu-Foca, D. Petrylak, R. Taub, L. Vahdat, Bing-Mae Cheng, M. Pegram, K. Knutson, R. Clynes (2007)
Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and ChemotherapyClinical Cancer Research, 13
-
G Schuler (2010)
10.1002/eji.201040630Eur. J. Immunol., 40
-
R. Schreiber, L. Old, M. Smyth (2011)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 331
-
D. Kohn, G. Dotti, R. Brentjens, B. Savoldo, M. Jensen, L. Cooper, C. June, S. Rosenberg, M. Sadelain, H. Heslop (2011)
CARs on track in the clinic.Molecular therapy : the journal of the American Society of Gene Therapy, 19 3
-
L. Emens, J. Asquith, J. Leatherman, B. Kobrin, S. Petrik, M. Laiko, J. Levi, M. Daphtary, B. Biedrzycki, A. Wolff, V. Stearns, M. Disis, X. Ye, S. Piantadosi, J. Fetting, N. Davidson, E. Jaffee (2009)
Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 35
-
Ilaria Marigo, L. Dolcetti, P. Serafini, P. Zanovello, V. Bronte (2008)
Tumor‐induced tolerance and immune suppression by myeloid derived suppressor cellsImmunological Reviews, 222
-
D. Pardoll (2003)
Does the immune system see tumors as foreign or self?Annual review of immunology, 21
-
M. Cheever, J. Schlom, Louis Weiner, H. Lyerly, Mary Disis, A. Greenwood, Oren Grad, William Nelson (2008)
Translational Research Working Group Developmental Pathway for Immune Response ModifiersClinical Cancer Research, 14
-
L. Johnson, R. Morgan, M. Dudley, L. Cassard, J. Yang, M. Hughes, U. Kammula, R. Royal, R. Sherry, J. Wunderlich, C. Lee, N. Restifo, S. Schwarz, Alexandria Cogdill, R. Bishop, Hung Kim, C. Brewer, Susan Rudy, C. Vanwaes, Jeremy Davis, A. Mathur, R. Ripley, Debbie-Ann Nathan, C. Laurencot, S. Rosenberg (2009)
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood, 114 3
-
M. Dudley, J. Wunderlich, J. Yang, P. Hwu, D. Schwartzentruber, S. Topalian, R. Sherry, F. Marincola, S. Leitman, C. Seipp, Linda Rogers-Freezer, K. Morton, Azam Nahvi, S. Mavroukakis, D. White, S. Rosenberg (2002)
A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic MelanomaJournal of Immunotherapy, 25
-
Tomoki Ito, Yui-Hsi Wang, Omar Duramad, S. Hanabuchi, Olivia Perng, M. Gilliet, F. Qin, Yong‐jun Liu (2006)
OX40 ligand shuts down IL-10-producing regulatory T cellsProceedings of the National Academy of Sciences, 103
-
E. Small, Paige Fratesi, D. Reese, G. Strang, R. Laus, M. Peshwa, F. Valone (2000)
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 18 23
-
S. Rosenberg, J. Yang, N. Restifo (2004)
Cancer immunotherapy: moving beyond current vaccinesNature Medicine, 10
-
AJ Muller (2006)
10.1038/nrc1929Nature Rev. Cancer, 6
-
J. Kochenderfer, W. Wilson, J. Janik, M. Dudley, M. Stetler-Stevenson, S. Feldman, I. Maric, M. Raffeld, Debbie-Ann Nathan, B. Lanier, R. Morgan, S. Rosenberg (2010)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.Blood, 116 20
-
L. Apetoh, F. Ghiringhelli, A. Tesnière, A. Tesnière, A. Tesnière, M. Obeid, M. Obeid, M. Obeid, Carla Ortiz, Carla Ortiz, Carla Ortiz, A. Criollo, A. Criollo, A. Criollo, G. Mignot, G. Mignot, G. Mignot, M. Maiuri, E. Ullrich, E. Ullrich, E. Ullrich, P. Saulnier, Huan Yang, S. Amigorena, B. Ryffel, F. Barrat, P. Saftig, F. Lévi, F. Lévi, R. Lidereau, C. Noguès, J. Mira, A. Chompret, V. Joulin, F. Clavel-Chapelon, J. Bourhis, F. André, S. Delaloge, T. Tursz, G. Kroemer, G. Kroemer, G. Kroemer, L. Zitvogel (2007)
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapyNature Medicine, 13
-
F. Ghiringhelli, C. Ménard, P. Puig, S. Ladoire, S. Roux, F. Martin, E. Solary, A. Cesne, L. Zitvogel, B. Chauffert (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patientsCancer Immunology, Immunotherapy, 56
-
J. Hamanishi, M. Mandai, Masashi Iwasaki, Taku Okazaki, Yoshimasa Tanaka, K. Yamaguchi, T. Higuchi, H. Yagi, K. Takakura, N. Minato, T. Honjo, S. Fujii (2007)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 104
-
D. McDermott, M. Atkins (2004)
Application of IL-2 and other cytokines in renal cancerExpert Opinion on Biological Therapy, 4
-
J. Kirkwood, J. Ibrahim, J. Sosman, V. Sondak, S. Agarwala, M. Ernstoff, U. Rao (2001)
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 9
-
Hiroyuki Nishimura, Taku Okazaki, Yoshimasa Tanaka, K. Nakatani, M. Hara, A. Matsumori, S. Sasayama, Akira Mizoguchi, H. Hiai, N. Minato, Tasuku Honjo (2001)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.Science, 291 5502
-
D. Porter, M. Roth, C. McGarigle, J. Ferrara, J. Antin (1994)
Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia.The New England journal of medicine, 330 2
-
A. Parsa, J. Waldron, Amith Panner, C. Crane, I. Parney, J. Barry, Kristine Cachola, Joseph Murray, T. Tihan, M. Jensen, P. Mischel, D. Stokoe, R. Pieper (2007)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in gliomaNature Medicine, 13
-
P. Robbins, R. Morgan, S. Feldman, J. Yang, R. Sherry, M. Dudley, J. Wunderlich, Azam Nahvi, L. Helman, C. Mackall, U. Kammula, M. Hughes, N. Restifo, M. Raffeld, C. Lee, Catherine Levy, Yong Li, M. El-Gamil, S. Schwarz, C. Laurencot, S. Rosenberg (2011)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 7
-
Yangbing Zhao, E. Moon, C. Carpenito, C. Paulos, Xiaojun Liu, A. Brennan, A. Chew, R. Carroll, J. Scholler, B. Levine, S. Albelda, C. June (2010)
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.Cancer research, 70 22
-
H. Büning, W. Uckert, K. Cichutek, R. Hawkins, H. Abken (2010)
Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.Human gene therapy, 21 9
-
Toshio Watanabe, Antonio Bertoletti, Antonio Bertoletti, T. Tanoto, T. Tanoto (2010)
PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infectionJournal of Viral Hepatitis, 17
-
M Dougan, G Dranoff (2009)
Immune therapy for cancerAnnu. Rev. Immunol., 27
-
T. Boon, P. Coulie, B. Eynde, P. Bruggen (2006)
Human T cell responses against melanoma.Annual review of immunology, 24
-
R. Shrimali, Zhiya Yu, M. Theoret, D. Chinnasamy, N. Restifo, S. Rosenberg (2010)
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.Cancer research, 70 15
-
R. Morgan, M. Dudley, S. Rosenberg (2010)
Adoptive Cell Therapy: Genetic Modification to Redirect Effector Cell SpecificityThe Cancer Journal, 16
-
J. Greiner, L. Bullinger, B. Guinn, H. Döhner, M. Schmitt (2008)
Leukemia-Associated Antigens Are Critical for the Proliferation of Acute Myeloid Leukemia CellsClinical Cancer Research, 14
-
M. Dudley, J. Yang, R. Sherry, M. Hughes, R. Royal, U. Kammula, P. Robbins, Jianping Huang, D. Citrin, S. Leitman, J. Wunderlich, N. Restifo, Armen Thomasian, Stephanie Downey, F. Smith, J. Klapper, K. Morton, C. Laurencot, D. White, S. Rosenberg (2008)
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 32
-
Natasha Fewkes, C. Mackall (2010)
Novel Gamma-Chain Cytokines as Candidate Immune Modulators in Immune Therapies for CancerThe Cancer Journal, 16
-
C. Bouzin, Agnès Brouet, J. Vriese, Julie Dewever, O. Féron (2007)
Effects of Vascular Endothelial Growth Factor on the Lymphocyte-Endothelium Interactions: Identification of Caveolin-1 and Nitric Oxide as Control Points of Endothelial Cell Anergy1The Journal of Immunology, 178
-
K. Kakimi, A. Kondo, H. Matsushita (2012)
[Dendritic cells for cancer immunotherapy].Nihon rinsho. Japanese journal of clinical medicine, 70 12
-
D. Porter, B. Levine, M. Kalos, A. Bagg, C. June (2011)
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.The New England journal of medicine, 365 8
-
D. Nagorsen, R. Bargou, D. Rüttinger, P. Kufer, P. Baeuerle, G. Zugmaier (2009)
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomabLeukemia & Lymphoma, 50
-
S Aggarwal, MF Pittenger (2005)
Human mesenchymal stem cells modulate allogeneic immune cell responsesBlood, 105
-
G. Kenter, M. Welters, A. Valentijn, M. Lowik, Dorien Meer, A. Vloon, Farah Essahsah, Lorraine Fathers, R. Offringa, J. Drijfhout, A. Wafelman, J. Oostendorp, G. Fleuren, S. Burg, C. Melief (2009)
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.The New England journal of medicine, 361 19
-
Elizabeth Manning, John Ullman, J. Leatherman, J. Asquith, T. Hansen, T. Armstrong, D. Hicklin, E. Jaffee, L. Emens (2007)
A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based MechanismClinical Cancer Research, 13
-
P. Robbins, Yutaka Kawakami (1996)
Human tumor antigens recognized by T cells.Current opinion in immunology, 8 5
-
N. Leffers, A. Lambeck, M. Gooden, B. Hoogeboom, Rinze Wolf, I. Hamming, B. Hepkema, P. Willemse, B. Molmans, H. Hollema, J. Drijfhout, W. Sluiter, A. Valentijn, L. Fathers, J. Oostendorp, A. Zee, C. Melief, S. Burg, T. Daemen, H. Nijman (2009)
Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trialInternational Journal of Cancer, 125
-
T. Robak (2009)
GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies.Current opinion in investigational drugs, 10 6
-
G. Phan, J. Yang, R. Sherry, P. Hwu, S. Topalian, D. Schwartzentruber, N. Restifo, Leah Haworth, C. Seipp, Linda Freezer, K. Morton, S. Mavroukakis, P. Duray, S. Steinberg, J. Allison, T. Davis, S. Rosenberg (2003)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProceedings of the National Academy of Sciences of the United States of America, 100
-
H. Watanabe, F. Wells, M. Major (2010)
Clearance of hepatitis C in chimpanzees is associated with intrahepatic T‐cell perforin expression during the late acute phaseJournal of Viral Hepatitis, 17
-
W. Weng, R. Levy (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 21
-
P. Waterhouse, J. Penninger, E. Timms, A. Wakeham, A. Shahinian, Kelvin Lee, C. Thompson, H. Griesser, T. Mak (1995)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4Science, 270
-
H. Hausen (2009)
Papillomaviruses in the causation of human cancers - a brief historical account.Virology, 384 2
-
S Aggarwal (2005)
10.1182/blood-2004-04-1559Blood, 105
-
Gail Phillips, Guangmin Li, D. Dugger, Lisa Crocker, Kathryn Parsons, Elaine Mai, W. Blättler, J. Lambert, R. Chari, R. Lutz, W. Wong, Frederic Jacobson, H. Koeppen, R. Schwall, S. Kenkare-Mitra, S. Spencer, M. Sliwkowski (2008)
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate.Cancer research, 68 22
-
J. Machiels, R. Reilly, L. Emens, Anne Ercolini, R. Lei, D. Weintraub, Francesca Okoye, E. Jaffee (2001)
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.Cancer research, 61 9
-
S. Rosenberg, J. Yannelli, J. Yang, S. Topalian, D. Schwartzentruber, J. Weber, D. Parkinson, C. Seipp, J. Einhorn, D. White (1994)
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.Journal of the National Cancer Institute, 86 15
-
R. Buckanovich, A. Facciabene, Sarah Kim, F. Benencia, D. Sasaroli, K. Balint, D. Katsaros, A. O’Brien-Jenkins, P. Gimotty, G. Coukos (2008)
Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapyNature Medicine, 14
-
RM Steinman, D Hawiger, MC Nussenzweig (2003)
Tolerogenic dendritic cellsAnnu. Rev. Immunol., 21
-
A. Ohta, E. Gorelik, Simon Prasad, F. Ronchese, D. Lukashev, M. Wong, Xiaojun Huang, Sheila Caldwell, Kebin Liu, Patrick Smith, Jiang-fan Chen, E. Jackson, S. Apasov, S. Abrams, M. Sitkovsky (2006)
A2A adenosine receptor protects tumors from antitumor T cellsProceedings of the National Academy of Sciences, 103
-
A. Hurwitz, Tina Yu, D. Leach, J. Allison (1998)
CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.Proceedings of the National Academy of Sciences of the United States of America, 95 17
-
G Schuler (2010)
Dendritic cells in cancer immunotherapyEur. J. Immunol., 40
-
J. Yang, M. Hughes, U. Kammula, R. Royal, R. Sherry, S. Topalian, K. Suri, Catherine Levy, T. Allen, S. Mavroukakis, I. Lowy, D. White, S. Rosenberg (2007)
Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and HypophysitisJournal of Immunotherapy, 30
-
M. Dudley, J. Wunderlich, P. Robbins, J. Yang, P. Hwu, D. Schwartzentruber, S. Topalian, R. Sherry, N. Restifo, Amy Hubicki, M. Robinson, M. Raffeld, P. Duray, C. Seipp, Linda Rogers-Freezer, K. Morton, S. Mavroukakis, D. White, S. Rosenberg (2002)
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor LymphocytesScience, 298
-
D. Lynch (2008)
The promise of 4‐1BB (CD137)‐mediated immunomodulation and the immunotherapy of cancerImmunological Reviews, 222
-
G. Gross, T. Waks, Z. Eshhar (1989)
Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.Proceedings of the National Academy of Sciences of the United States of America, 86 24
-
The authors summarize the argument for using a different set of criteria to evaluate the efficacy of immunotherapies given the mechanistic differences from conventional anticancer drugs -
Aimin Jiang, O. Bloom, S. Ono, W. Cui, J. Unternaehrer, Shan Jiang, J. Whitney, J. Connolly, J. Banchereau, I. Mellman (2007)
Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation.Immunity, 27 4
-
L. Novellino, C. Castelli, G. Parmiani (2005)
A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 54
-
J. Galon, A. Costes, F. Sánchez-Cabo, A. Kirilovsky, B. Mlecnik, C. Lagorce-Pagès, M. Tosolini, M. Camus, A. Berger, P. Wind, F. Zinzindohoué, P. Bruneval, P. Cugnenc, Z. Trajanoski, W. Fridman, F. Pagès (2006)
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical OutcomeScience, 313
-
K. Wing, Yasush Onishi, P. Prieto-Martin, Tomoyuki Yamaguchi, M. Miyara, Z. Fehérvári, T. Nomura, S. Sakaguchi (2008)
CTLA-4 Control over Foxp3+ Regulatory T Cell FunctionScience, 322
-
Lin Wang, T. Yi, M. Kortylewski, D. Pardoll, D. Zeng, Hua Yu (2009)
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathwayThe Journal of Experimental Medicine, 206
-
A. Loren, D. Porter (2008)
Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantationBone Marrow Transplantation, 41
-
Q. Gao, Xiao-Ying Wang, S. Qiu, I. Yamato, M. Sho, Y. Nakajima, Jian Zhou, Bai-zhou Li, Yinghong Shi, Yong-sheng Xiao, Yang Xu, Jia Fan (2009)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular CarcinomaClinical Cancer Research, 15
-
S. Topalian, D. Solomon, F. Avis, A. Chang, D. Freerksen, W. Linehan, M. Lotze, C. Robertson, C. Seipp, P. Simon (1988)
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 6 5
-
F. Hodi, S. O'Day, D. McDermott, R. Weber, J. Sosman, J. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, Jessica Hassel, W. Akerley, A. Eertwegh, J. Lutzky, P. Lorigan, Julia Vaubel, G. Linette, D. Hogg, C. Ottensmeier, C. Lebbé, C. Peschel, I. Quirt, Joseph Clark, J. Wolchok, J. Weber, Jason Tian, M. Yellin, G. Nichol, A. Hoos, W. Urba (2010)
Improved survival with ipilimumab in patients with metastatic melanoma.The New England journal of medicine, 363 8
-
M. Curran, Welby Montalvo, H. Yagita, J. Allison (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences, 107
-
M. Pule, B. Savoldo, G. Myers, C. Rossig, H. Russell, G. Dotti, M. Huls, E. Liu, A. Gee, Z. Mei, E. Yvon, H. Weiss, Hao Liu, C. Rooney, H. Heslop, M. Brenner (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 14
-
C. Chambers, M. Kuhns, J. Egen, J. Allison (2001)
CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.Annual review of immunology, 19
-
A. Mellor, D. Munn (2004)
Ido expression by dendritic cells: tolerance and tryptophan catabolismNature Reviews Immunology, 4
-
T. Curiel, G. Coukos, L. Zou, Xavier Alvarez, P. Cheng, P. Mottram, Melina Evdemon-Hogan, J. Conejo-Garcia, Lin Zhang, M. Burow, Yun Zhu, Shuang Wei, Ilona Kryczek, B. Daniel, Alan Gordon, L. Myers, A. Lackner, M. Disis, K. Knutson, Lieping Chen, W. Zou (2004)
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalNature Medicine, 10
-
P. Chapman, A. Hauschild, C. Robert, J. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbé, T. Jouary, D. Schadendorf, A. Ribas, S. O'Day, J. Sosman, J. Kirkwood, A. Eggermont, B. Dréno, K. Nolop, Jiang Li, B. Nelson, J. Hou, Richard Lee, K. Flaherty, G. McArthur (2011)
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.The New England journal of medicine, 364 26
-
Taku Okazaki, I. Okazaki, Jian Wang, D. Sugiura, Fumio Nakaki, Taku Yoshida, Y. Kato, S. Fagarasan, M. Muramatsu, T. Eto, K. Hioki, T. Honjo (2011)
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in miceThe Journal of Experimental Medicine, 208
-
I. Mellman, R. Steinman (2001)
Dendritic Cells Specialized and Regulated Antigen Processing MachinesCell, 106
-
M Dougan (2009)
10.1146/annurev.immunol.021908.132544Annu. Rev. Immunol., 27
-
T. Golovina, R. Vonderheide (2010)
Regulatory T Cells: Overcoming Suppression of T-Cell ImmunityThe Cancer Journal, 16
-
A. Facciabene, Xiao-hui Peng, I. Hagemann, K. Balint, A. Barchetti, Li-ping Wang, P. Gimotty, C. Gilks, P. Lal, Lin Zhang, G. Coukos (2011)
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cellsNature, 475
-
Esperanza, Papadopoulos, Matthew, Carabasi, Lilian Reich, N. Collins, F. Boulad, Castro-Malaspina, Barrett, Childs, Alfred, N. Kernan, T. Small, James, Young, R. O'reilly (1995)
Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease.Blood, 86 4
-
N. Segal, D. Parsons, K. Peggs, V. Velculescu, K. Kinzler, B. Vogelstein, J. Allison (2008)
Epitope landscape in breast and colorectal cancer.Cancer research, 68 3
-
Sjarlot Kooi, Huazhong Zhang, R. Patenia, C. Edwards, C. Platsoucas, R. Freedman (1996)
HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.Cellular immunology, 174 2
-
G. Suntharalingam, M. Perry, S. Ward, S. Brett, A. Castello-Cortes, Michael Brunner, N. Panoskaltsis (2006)
Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.The New England journal of medicine, 355 10
-
Ivana Ferrer, M. Wagener, J. Robertson, A. Turner, K. Araki, R. Ahmed, A. Kirk, C. Larsen, M. Ford (2010)
Cutting Edge: Rapamycin Augments Pathogen-Specific but Not Graft-Reactive CD8+ T Cell ResponsesThe Journal of Immunology, 185
-
D. Gabrilovich, S. Nagaraj (2009)
Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 9
-
Lin Zhang, J. Conejo-Garcia, D. Katsaros, P. Gimotty, M. Massobrio, G. Regnani, A. Makrigiannakis, H. Gray, K. Schlienger, M. Liebman, S. Rubin, G. Coukos (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.The New England journal of medicine, 348 3
-
M. Besser, R. Shapira-Frommer, A. Treves, D. Zippel, O. Itzhaki, Liat Hershkovitz, Daphna Levy, A. Kubi, E. Hovav, Natalia Chermoshniuk, B. Shalmon, I. Hardan, R. Catane, G. Markel, S. Apter, A. Ben-nun, I. Kuchuk, A. Shimoni, A. Nagler, J. Schachter (2010)
Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma PatientsClinical Cancer Research, 16
-
J. Vansteenkiste, M. Zielinski, A. Linder, J. Dahabre, E. Esteban, W. Malinowski, J. Jassem, B. Passlick, F. Lehmann, V. Brichard (2007)
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)Journal of Clinical Oncology, 25
-
M. Obeid, A. Tesnière, F. Ghiringhelli, G. Fimia, L. Apetoh, J. Perfettini, M. Castedo, G. Mignot, T. Panaretakis, N. Casares, D. Métivier, N. Larochette, P. Endert, F. Ciccosanti, M. Piacentini, L. Zitvogel, G. Kroemer (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine, 13
-
R. Nahta, F. Esteva (2006)
Herceptin: mechanisms of action and resistance.Cancer letters, 232 2
-
J. Shin, Il‐Hee Yoon, Jung‐Sik Kim, Bongi Kim, Chung-Gyu Park (2009)
Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells.Cellular immunology, 256 1-2
-
The authors summarize the current state of the art use of autologous dendritic cell vaccines -
D. Leach, M. Krummel, J. Allison (1996)
Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 271
-
E. Calhoon (1988)
Immune therapy of cancer.The Journal of the Oklahoma State Medical Association, 81 11
- Publisher
- Springer Journals
- Copyright
- Copyright © Springer Nature Limited 2011
- Subject
- Science, Humanities and Social Sciences, multidisciplinary; Science, Humanities and Social Sciences, multidisciplinary; Science, multidisciplinary
- ISSN
- 0028-0836
- eISSN
- 1476-4687
- DOI
- 10.1038/nature10673
- Publisher site
- See Article on Publisher Site
Abstract
An overview of the latest advances in cancer immunotherapy.
Journal
Nature – Springer Journals
Published: Dec 22, 2011